{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:59:23Z","timestamp":1785387563895,"version":"3.55.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The fibrosis-4 (FIB-4) index incorporates age, aminotransferases, and platelet count and is widely used for liver fibrosis risk stratification. Because age is part of its formula and strongly associated with diabetes, apparent associations between FIB-4 and prevalent diabetes may reflect age-related confounding rather than an independent hepatic signal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional analysis of 35,213 adults from NHANES 2003\u20132018 and 32,456 adults from a hospital-based health examination population in Hainan, China (2022-2025). Survey-weighted and conventional multivariable logistic regression evaluated FIB-4 continuously and by tertiles. Additional analyses assessed nonlinear associations, age parameterization, collinearity, liver-related exclusions, age-free liver indices, and incremental model performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In age-group-adjusted NHANES models, each 1-unit increase in FIB-4 was associated with higher odds of prevalent diabetes (OR, 1.13; 95% CI, 1.06-1.22). After replacing age categories with continuous age, this association was attenuated and no longer significant (OR, 1.03; 95% CI, 0.95-1.12;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.518). In the hospital-based population, where Model 3 already used continuous age, the association persisted (OR, 1.36; 95% CI, 1.25-1.48). Collinearity diagnostics did not indicate problematic multicollinearity. Adding FIB-4 to traditional diabetes predictors did not improve NHANES discrimination (AUC, 0.822 vs 0.822) and produced only minimal improvement in the hospital-based population (AUC, 0.756 vs 0.758).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The association between FIB-4 and prevalent diabetes was sensitive to age modeling and differed across datasets. FIB-4 provided little incremental model performance beyond traditional diabetes predictors. These cross-sectional findings do not support FIB-4 as an independent screening, diagnostic, or predictive tool for diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1881759","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:21:29Z","timestamp":1785385289000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of the fibrosis-4 index with prevalent diabetes among adults: a cross-sectional analysis of NHANES 2003\u20132018 and a Chinese hospital-based health examination population"],"prefix":"10.3389","volume":"17","author":[{"given":"Zeng","family":"Chen","sequence":"first","affiliation":[{"name":"College of Sports Medicine, Wuhan Sports University","place":["Wuhan, China"]},{"name":"Department of Rehabilitation Medicine, Geriatric Hospital of Hainan","place":["Hainan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Geriatric Hospital of Hainan","place":["Hainan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Geriatric Hospital of Hainan","place":["Hainan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Hu","sequence":"additional","affiliation":[{"name":"College of Sports Medicine, Wuhan Sports University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"B2","doi-asserted-by":"publisher","first-page":"6613827","DOI":"10.1155\/2021\/6613827","article-title":"NAFLD, insulin resistance, and diabetes mellitus type 2","volume":"2021","author":"Maru\u0161i\u0107","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5005\/jp\/books\/10445_45","article-title":"Non-alcoholic fatty liver disease and type\u20092 diabetes: An update","volume":"13","author":"Lee","year":"2022","journal-title":"J Diabetes Invest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: An updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2016.06.005","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD)","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocrine Pract"},{"key":"B6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1159\/000539371","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the L","year":"2024","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000845","article-title":"AASLD practice guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100780","DOI":"10.1016\/j.lanepe.2023.100780","article-title":"Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: A longitudinal cohort study","volume":"36","author":"Anstee","year":"2024","journal-title":"Lancet Regional Health \u2013 Europe"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1172178","article-title":"Association between FIB-4, all-cause mortality, cardiovascular mortality, and cardiovascular disease risk among diabetic individuals: NHANES 1999\u20132008","volume":"10","author":"Guan","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection\u2020\u2021","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and classification of diabetes: Standards of care in diabetes\u20142024","volume":"47","year":"2023","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-019-00494-6","article-title":"Principles of confounder selection","volume":"34","author":"VanderWeele","year":"2019","journal-title":"Eur J Epidemiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1513\/annalsats.201808-564ps","article-title":"Control of confounding and reporting of results in causal inference studies. Guidance for authors from editors of respiratory, sleep, and critical care journals","volume":"16","author":"Lederer","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: Standards of care in diabetes\u20142025","volume":"48","year":"2024","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/er.2019-00034","article-title":"The liver as an endocrine organ-linking NAFLD and insulin resistance","volume":"40","author":"Watt","year":"2019","journal-title":"Endocr Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: Revisited after a decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076388","article-title":"Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: Nationwide population based study","volume":"384","author":"Kim","year":"2024","journal-title":"Bmj"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-025-04094-z","article-title":"FIB-4, a surrogate marker of liver fibrosis, predicts mortality and adverse events after acute myocardial infarction","author":"Gorur","year":"2025","journal-title":"Intern Emerg Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.102176","article-title":"Is FIB-4 the right tool for screening for liver fibrosis","volume":"31","author":"Heyens","year":"2025","journal-title":"Ann Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-023-08093-8","article-title":"Real-world primary care data comparing ALT and FIB-4 in predicting future severe liver disease outcomes","volume":"38","author":"Schreiner","year":"2023","journal-title":"J Gen Internal Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: A multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100925","article-title":"FIB-4 and APRI for cirrhosis detection in a privately insured national cohort","volume":"6","author":"Parikh","year":"2024","journal-title":"JHEP Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15131598","article-title":"Comparing FIB-4, VCTE, pSWE, 2D-SWE, and MRE thresholds and diagnostic accuracies for detecting hepatic fibrosis in patients with MASLD: A systematic review and meta-analysis","volume":"15","author":"Wilson","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2024.100457","article-title":"Liver fibrosis according to diabetes status and relation to cardiovascular risk and mortality in US adults","volume":"46","author":"Bang","year":"2024","journal-title":"Am Heart J Plus"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23263","article-title":"Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease","volume":"29","author":"Barb","year":"2021","journal-title":"Obesity"},{"key":"B30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12902-022-01042-2","article-title":"Serum liver enzymes and diabetes from the Rafsanjan cohort study","volume":"22","author":"Noroozi Karimabad","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults: A review","volume":"335","author":"Tilg","year":"2026","journal-title":"Jama"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2021.07.001","article-title":"Diabetes mellitus increases the risk of significant hepatic fibrosis in patients with non-alcoholic fatty liver disease","volume":"12","author":"Chhabra","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1551472","article-title":"Cross-sectional study on the association between the fibrosis-4 index and co-occurring myocardial infarction in Chinese patients with type 2 diabetes mellitus","volume":"16","author":"Sun","year":"2025","journal-title":"Front Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s43066-025-00442-y","article-title":"Comparison of FIB-4, APRI and AST\/ALT ratio with FibroScan in patients with NAFLD and type 2 diabetes: A single-center study from Bangladesh","volume":"15","author":"Alam","year":"2025","journal-title":"Egyptian Liver J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: An updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjph-2024-002020","article-title":"Impact of type 2 diabetes on the risk of cardiovascular disease and cardiovascular mortality in patients with non-alcoholic fatty liver disease: A nationwide population-based study","volume":"3","author":"Roh","year":"2025","journal-title":"BMJ Public Health"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15259","article-title":"Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea","volume":"42","author":"Kim","year":"2022","journal-title":"Liver Int"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2025.101014","article-title":"Relationships among fibrosis-4, triglyceride-glucose index, and cardiovascular disease: Evidence from the NHANES 2003-2018","volume":"22","author":"Ye","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s12875-025-03039-x","article-title":"Prevalence of advanced fibrosis risk using FIB-4 in patients with type 2 diabetes and its associated factors: A cross-sectional study in a primary care unit of a university hospital in Southern Thailand","volume":"26","author":"Ananchaisarp","year":"2025","journal-title":"BMC Primary Care"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14222500","article-title":"Modified FIB-4 index in type 2 diabetes mellitus with steatosis: A non-linear predictive model for advanced hepatic fibrosis","volume":"14","author":"Kim","year":"2024","journal-title":"Diagnostics"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073538","article-title":"Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: Checklist for systematic reviews and meta-analyses (TRIPOD-SRMA)","volume":"381","author":"Snell","year":"2023","journal-title":"Bmj"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.12126","article-title":"Discrimination and calibration of clinical prediction models: Users' guides to the medical literature","volume":"318","author":"Alba","year":"2017","journal-title":"Jama"},{"key":"B44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","article-title":"Calibration: The Achilles heel of predictive analytics","volume":"17","author":"Van Calster","year":"2019","journal-title":"BMC Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1881759\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:21:30Z","timestamp":1785385290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1881759\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":44,"alternative-id":["10.3389\/fendo.2026.1881759"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1881759","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1881759"}}